Medical Device News

LayerBio Granted U.S. Patent for OcuRing™ Drug Delivery Platform

Novel sustained-release technology has potential to eliminate the need for eye drops after cataract surgery.

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

LayerBio, Inc. (LayerBio), an ophthalmology therapeutics company, announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441.

“This patent issuance marks an important milestone for the OcuRing platform and recognition of novelty and uniqueness of our drug delivery technology,” said Kenneth Mandell, M.D., Ph.D., CEO and Founder of LayerBio. “LayerBio will continue to develop our portfolio of patents for the OcuRing platform in order to produce safer, more effective and better-tolerated alternatives to topical eye drops for patients undergoing cataract surgery.”

The patent provides coverage for a variety of drug product compositions, methods of use, and delivery systems for LayerBio’s propriety bioerodible drug delivery rings that release therapeutic medications for use in cataract surgery.

“OcuRing has the potential to transform the standard of care for cataract surgery,” said Dr. Richard Lindstrom, M.D., a leading expert in cataract surgery and member of LayerBio’s Board of Directors. “By automatically releasing medicine inside the eye after cataract surgery, OcuRing™ can ensure compliance, improve outcomes and enhance the overall patient experience.”

LayerBio’s lead product candidate OcuRing-K™ is a sustained-release nonsteroidal anti-inflammatory drug (NSAID) formulation of ketorolac, an opioid-sparing analgesic with proven efficacy for reducing inflammation and pain associated with cataract surgery.

“OcuRing-K is a game-changer because it provides all of the benefits of an NSAID without the ocular surface side effects,” said Dr. Eric Donnenfeld, M.D., chair of LayerBio’s medical advisory board. “By delivering ketorolac directly inside the eye, it maintains a therapeutic plateau and essentially eliminates the risks of surface corneal toxicity associated with NSAID eye drops.”

In addition to NSAIDs, the OcuRing™ platform has the capacity to deliver other ophthalmic medications, including corticosteroids, antibiotics and glaucoma medications. LayerBio will continue to develop innovative products that address unmet medical needs for cataract surgery and other eye conditions.

Medical Device News Magazine
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Ultrahuman Announces its App Store ‘PowerPlugs’ with the World’s First AFib Detection Technology on a Smart Ring

Recognizing each individual’s health journey is unique, PowerPlugs enable people to choose and focus on the aspects of their health that matter most. It’s designed for highly personalized health insights, ensuring that every individual can personalize their health tracking to their unique needs and goals.

VisionAir Solutions Celebrates Milestone and New Collaboration

This achievement marks VisionAir Solutions commitment to bringing technological innovation to pulmonary medicine. Since its acquisition by Theken Companies last year, VAS has over doubled its growth and continues to demonstrate industry adoption and the advantages of personalized healthcare.

Valencia Technologies Announces CMS Publication of 2025 Medicare Proposed Rule for eCoin® Procedure

Ann Decker, VP of Reimbursement for Valencia Technologies, stated, "The cumulative effect of the proposed 2025 continuation of APC assignment 5464, the improved ASC payment rate, and the recognition of ITNS as a minimally invasive OAB treatment option in the recently updated guidelines by the American Urological Association (AUA) and the Society of Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU), underscores that the eCoin ITNS system will have a strong reimbursement pathway throughout 2025 and beyond.